In this article, we discuss the 5 best robotics stocks under $10. In order to take a look at our detailed analysis of the robotics industry and some more stocks, go directly to 11 Best Robotics Stocks Under $10.
5. ReWalk Robotics Ltd. (NASDAQ:RWLK)
Number of Hedge Fund Holders: 3
Share Price (as of May 20): $0.88
ReWalk Robotics Ltd. (NASDAQ:RWLK) ranks next on our list of the best robotic stocks to buy under $10. It develops and commercializes robotic exoskeletons for individuals with mobility impairments or other medical conditions. The Israeli firm offers ReWalk Personal and ReWalk Rehabilitation, exoskeletons used by paraplegic individuals or patients with spinal cord injuries. ReWalk Robotics Ltd. (NASDAQ:RWLK) was the first firm to receive FDA approval for its exoskeletons in the United States.
In March, a British man paralyzed from the waist down earned a Guinness World Record by climbing to the top of London’s 225 metre tall Leadenhall Building while donning a wearable robotic exoskeleton by ReWalk Robotics Ltd. (NASDAQ:RWLK). In November, FDA (Food and Drug Administration) granted the firm’s ReBoot device the designation of a Breakthrough Device. The lightweight, battery-powered exo-suit will assist individuals with reduced ankle functions owing to neurological injuries.
The leading shareholder of ReWalk Robotics Ltd. (NASDAQ:RWLK) in the first quarter was Hal Mintz’ Sabby Capital, which held a $1.47 million stake in the company.
Out of the 924 elite hedge funds tracked by Insider Monkey as at the end of Q4 2021, 3 reported ownership of stakes in ReWalk Robotics Ltd. (NASDAQ:RWLK) with a combined value of $1.82 million.
4. Viomi Technology Co., Ltd (NASDAQ:VIOT)
Number of Hedge Fund Holders: 5
Share Price (as of May 20): $1.54
Viomi Technology Co., Ltd (NASDAQ:VIOT) is a Chinese firm which sells internet-of-things (IoT) enabled smart home devices. These include smart kitchen products such as refrigerators and smart water kettles, sweeper robots, smart locks, and smart TV appliances. The firm has a strategic partnership with Xiaomi Corporation, and sells its products in China through online e-commerce stores as well as physical experience centers. As of May 20, Viomi Technology Co., Ltd (NASDAQ:VIOT) trade at a value of $1.54.
For the fourth quarter, the company posted earnings per share of $0.07, above estimates by $0.06. For FY2021, Viomi Technology Co., Ltd (NASDAQ:VIOT) posted net revenue of RMB 5.3 billion, at gross profit margin of 22.6% which increased 4% year-on-year.
At the conclusion of the fourth quarter, 5 hedge funds reported bullish bets on Viomi Technology Co., Ltd (NASDAQ:VIOT) shares. This was up from 4 hedge funds in the previous quarter. Billionaire Jim Simons’ was once again the top shareholder in an up-and-coming robotic stock, with a stake in Viomi Technology Co., Ltd (NASDAQ:VIOT) worth $115,000 in the first quarter of 2022.
3. Asensus Surgical, Inc. (NYSE:ASXC)
Number of Hedge Fund Holders: 6
Share Price (as of May 20): $0.41
Asensus Surgical, Inc. (NYSE:ASXC) is another robotic company which develops technology to enable minimally invasive surgery. The firm is based in North Carolina and was known as TransEnterix, Inc up until February 2021. It digitizes the interface between the surgeon and the patient, with its multi-port robotic system called Senhance Surgical which includes a camera for laparoscopic procedures and allows up to four arms to control robotic instruments. These systems are increasingly being purchased or leased by hospitals in the United States and around the globe, and the firm will likely see steady growth as hospital activity normalizes after the Covid slowdown.
6 hedge funds were long Asensus Surgical, Inc. (NYSE:ASXC) at the end of Q4 2021, with combined stakes valued at $4.56 million. This shows that investors are warming up to this exciting robotics company, as 3 hedge funds held $1.13 million worth of positions a quarter before.
2. Accuray Incorporated (NASDAQ:ARAY)
Number of Hedge Fund Holders: 20
Share Price (as of May 20): $2.17
Accuray Incorporated (NASDAQ:ARAY) is a top robotic stock to buy under $10. It has developed the CyberKnife, which offers image-guided robotic radio-surgery treatments for a range of cancerous tumors; and Tomo Therapy systems, which include integrated radiation therapy systems to treat cancers.
In December, Loop Capital analyst Jason Wittes initiated coverage of Accuray Incorporated (NASDAQ:ARAY) with a ‘Buy’ rating and $7.50 price target. Wittes holds that the firm “is finally in a position to grow and generated cash” given its higher commitment to R&D which has enabled the launch of multiple new products. The analyst notes that the firm enjoys a strong reputation in China, and is leveraging it with the launch of a competitive, low-cost type B product in the country. He sees this as a major opportunity for the firm.
Accuray Incorporated (NASDAQ:ARAY) posted its first quarter earnings at the end of April, and beat consensus estimates on earnings per share by $0.05. The company garnered more than $96 million in revenue for the quarter, also beating analysts’ estimates by $123,000.
At the end of the fourth quarter of 2021, 20 hedge funds in the database of Insider Monkey held stakes worth $98.99 million in Accuray Incorporated (NASDAQ:ARAY), compared to 18 in the preceding quarter worth $81.52 million.
1. Stereotaxis, Inc. (NASDAQ:STXS)
Number of Hedge Fund Holders: 23
Share Price (as of May 20): $1.80
Stereotaxis, Inc. (NASDAQ:STXS) manufactures robotic magnetic navigation (RMN) systems which enable minimally invasive endovascular surgeries. The firm’s technology provides surgeons with image-guided delivery of catheters and guidewires into blood vessels and chambers of the heart.
Loop Capital analyst Jason Wittes in January initiated coverage of Stereotaxis, Inc. (NASDAQ:STXS) with a ‘Buy’ rating and a $13 price target. The analyst noted that the firm has developed an advanced robotic platform for endovascular surgery that makes use of magnets as opposed to less effective mechanical arms or automated guidewires to move catheters through clogged vessels. He believes the company’s new catheter system launching later this year will “dramatically” enhance its growth and profitability profile. Craig-Hallum analyst Alex Nowak also gave Stereotaxis, Inc. (NASDAQ:STXS) a ‘Buy’ rating in January, along with a price target of $11.
23 hedge funds held positions in Stereotaxis, Inc. (NASDAQ:STXS) at the conclusion of the fourth quarter, as compared to 26 hedge funds a quarter before. The total value of Q4 hedge funds holdings was recorded at $179.8 million. In the first quarter, DAFNA Capital Management held a $51 million stake in Stereotaxis, Inc. (NASDAQ:STXS) which represented 13.29% of its total portfolio, and made it the firm’s largest shareholder.
The company posted $7.04 million in revenue for the first quarter, which exceeded estimates by $368,000. EPS was recorded in-line with estimates at -$0.06.
You can also take a look at 15 Largest Food Delivery Companies in the World and Bill Gates’ Stock Portfolio: Top 15 Picks
